Publication Target Date: July 14
Submission Deadline: July 11
Article Working Title: Pharmaceutical Manufacturing: Validation, Batch Integrity, and What a Cyber Incident Actually Costs
Editorial Brief: Pharmaceutical manufacturing operates under regulatory obligations that transform the cost calculus of a cyber incident. Batch records, validation states, and electronic audit trails are legal requirements under 21 CFR Part 11 and EU Annex 11. A cyber incident that compromises those records does not just stop production: it potentially invalidates product that cannot be released regardless of its physical quality. The article should examine what validated system state means in practice, what happens to that validation when an OT system is modified in response to an incident, and how regulatory agencies treat cyber incidents that affect GMP compliance. The OT architecture of pharmaceutical manufacturing, DCS, SCADA, MES, LIMS, and their interconnections, creates specific integration points where cybersecurity and regulatory compliance intersect. Patching a validated system restarts the validation process, which creates a direct conflict between cybersecurity response timelines and quality system requirements. Recovery after a cyber incident in pharma is not complete until the validated state is restored and documented, which takes significantly longer than technical system restoration. The article should quantify what that extended recovery means in production terms and what practitioners are doing to manage it.
